Stokes Capital Advisors LLC Acquires 920 Shares of Novo Nordisk A/S (NYSE:NVO)

Stokes Capital Advisors LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,655 shares of the company’s stock after buying an additional 920 shares during the period. Stokes Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,175,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the third quarter valued at about $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S during the third quarter valued at about $42,000. Carolina Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $48,000. Finally, M&R Capital Management Inc. lifted its position in shares of Novo Nordisk A/S by 260.5% during the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after buying an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NVO has been the subject of several analyst reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

NVO opened at $78.74 on Monday. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a 50-day simple moving average of $97.76 and a two-hundred day simple moving average of $117.05. The company has a market capitalization of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.